Granisetron Baxter (Granisetron)

Granisetron Baxter is indicated for the prevention and treatment of nausea and vomiting in specific clinical settings.

• Chemotherapy‑induced nausea and vomiting (CINV) in adult patients.
• Postoperative nausea and vomiting (PONV) following surgical procedures.
• Nausea associated with radiation therapy.
• Nausea related to diagnostic procedures that use emetogenic agents.
• Prophylaxis in patients receiving highly emetogenic chemotherapy.
• Adjunct therapy for patients who have not responded adequately to other antiemetics.

The safety profile of Granisetron Baxter includes both frequent and less common adverse events observed in clinical use.

Common

• Headache.
• Constipation or abdominal discomfort.
• Dizziness or light‑headed feeling.
• Transient injection site reactions such as erythema or pain.

Serious

• Severe allergic reactions such as anaphylaxis.
• Cardiac arrhythmias or QT interval prolongation.
• Serotonin syndrome when combined with other serotonergic agents.

When prescribing Granisetron Baxter, clinicians should consider several precautionary measures to ensure safe use.

• Assess patient history for hypersensitivity to granisetron or other 5‑HT3 antagonists.
• Use caution in patients with known cardiac conduction disorders or prolonged QT interval.
• Evaluate renal and hepatic function, especially in severe impairment.
• Monitor for signs of serotonin syndrome if combined with serotonergic drugs.
• Consider dose adjustments in elderly patients.
• Avoid use during pregnancy unless benefits outweigh risks.

Granisetron Baxter may interact with other medications, requiring attention to avoid adverse effects or reduced efficacy.

Avoid

• Concurrent use with other 5‑HT3 receptor antagonists (e.g., ondansetron) due to additive effects.
• Co‑administration with drugs that significantly prolong QT interval (e.g., certain antiarrhythmics, antipsychotics).
• Use with potent CYP3A4 inducers that may reduce granisetron exposure (e.g., rifampin).

Use with caution

• Serotonergic agents such as SSRIs, SNRIs, or tramadol, which may increase risk of serotonin syndrome.
• Antifungal agents like fluconazole that can modestly increase granisetron levels.
• Electrolyte disturbances (hypokalemia, hypomagnesemia) that predispose to cardiac effects.